Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastomaMartin J. van den Bent, Vassilis Golfinopoulos, Annemiek Walenkamp et al.|Neuro-Oncology|2020Cited by 8
ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406Martin J. van den Bent, Vassilis Golfinopoulos, Pim J. French et al.|Neuro-Oncology|2018Cited by 4